- FUSED HETEROCYCLIC RING COMPOUND
-
A compound represented by the following formula or a salt thereof, which has an GPR119 agonist action, is useful for the prophylaxis or treatment of diabetes, obesity and the like, and shows superior efficacy: wherein P: substituted 6-membered aromatic ring, Q: (substituted) 6-membered aromatic ring, A1: CR4aR4b, NR4c, O, S, SO or SO2 {R4a-4c: H etc.}, L1: (substituted) C1-5 alkylene, L2: a bond or (substituted) C1-3 alkylene, L3-4: (substituted) C1-3 alkylene, R1: H, X, CN, (substituted) hydrocarbon, (substituted) heterocycle or (substituted) OH, or (substituted) 4- to 8-membered (heterocyclic) ring together with A1, R2: H, CN, (substituted) hydrocarbon, and R3a: -COSRA1, (substituted) 5- or 6-membered aromatic ring {RA1: (substituted) hydrocarbon or (substituted) heterocycle}.
- -
-
Page/Page column 91
(2012/01/11)
-
- NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO
-
New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein X1, X2, X3, X4, Y1
- -
-
Page/Page column 33
(2011/01/12)
-
- COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
-
The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes (I).
- -
-
Page/Page column 24
(2010/10/03)
-
- MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO
-
The present invention relates to 4-[5-Methoxy-6-(2-methyl-6-[1,2,4]triazol-1-yl-pyridin-3-ylamino)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutically acceptable salts, solvates and hydrates thereof that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity. (Formula I)
- -
-
Page/Page column 12
(2009/12/05)
-
- PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS
-
Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR 119 G protein-coupled receptor modulator therapy. These novel compounds have the structure Formula I or Formula IA.
- -
-
Page/Page column 105-106
(2009/02/11)
-
- GPR119 AGONISTS FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS
-
The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly Type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.
- -
-
Page/Page column 66; 67
(2010/11/29)
-
- MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO
-
The present invention relates to 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methyl-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutically acceptable salts, solvates and hydrates thereof that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.
- -
-
Page/Page column 27-28
(2008/06/13)
-
- COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY
-
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
- -
-
Page/Page column 84
(2008/12/08)
-
- Processes for preparing pyrazolo[3,4-d]pyrimidine ethers
-
The present invention relates to processes for preparing pyrazolo[3,4-d]pyrimidine ether compounds that are modulators of glucose metabolism and therefore useful in the treatment of metabolic disorders such as diabetes and obesity.
- -
-
Page/Page column 17-18
(2008/06/13)
-
- Processes for preparing aromatic ethers
-
The present invention relates to processes for preparing aromatic ether compounds that are modulators of glucose metabolism and therefore useful in the treatment of metabolic disorders such as diabetes and obesity.
- -
-
Page/Page column 14-15
(2008/06/13)
-
